Catalyst Wire Dossier Catalyst Wire Dossier

IYUZEH

LATANOPROST OPHTHALMIC SOLUTION 0.005% · Thea Pharma Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IYUZEH, covering 2022-12-13 to 2024-09-16. Get the full timeline:

Most recent: FDA Approved: IYUZEH — Supplemental Application (Thea Pharma Inc.)

See pricing